Neutral
Our verdict — RBC Capital ranks #62 of 65 in our leaderboard: 9.5% hit rate on Regeneron Pharmaceuticals (21 scored calls on this stock), 9% average gain per call, -2 pts vs its sector.
Regeneron Pharmaceuticals (REGN) price target — analyst by analyst
Regeneron Pharmaceuticals · Health Care · ref. ETF XLV · price $753.12
By Rédaction JPI Invest · updated
In short — 17 price targets published on Regeneron Pharmaceuticals over 90 days: 9 bullish, 0 bearish (53% positive), median target $795. The highest-ranked firm to weigh in is Cantor Fitzgerald (rank 7, 58.6% hit rate). For each call below we show the firm's real track record — not just its opinion.
The last 17 analyst calls on REGN
Newest first. The "verdict" is our read on the firm, based on its past calls replayed against actual prices.
Bullish
Our verdict — Truist Securities ranks #50 of 65 in our leaderboard: 55% hit rate on Regeneron Pharmaceuticals (20 scored calls on this stock), 14.8% average gain per call, +3 pts vs its sector.
Neutral
Our verdict — Morgan Stanley ranks #48 of 65 in our leaderboard: 80% hit rate on Regeneron Pharmaceuticals (20 scored calls on this stock), 12.5% average gain per call, +3 pts vs its sector.
Bullish
Our verdict — JP Morgan ranks #36 of 65 in our leaderboard: 62.5% hit rate on Regeneron Pharmaceuticals (8 scored calls on this stock), 16% average gain per call, +4 pts vs its sector.
Bullish
Our verdict — Jefferies ranks #31 of 65 in our leaderboard: 50% hit rate on Regeneron Pharmaceuticals (6 scored calls on this stock), 16.8% average gain per call, +5 pts vs its sector.
Bullish
Our verdict — Argus Research ranks #46 of 65 in our leaderboard: 66.7% hit rate on Regeneron Pharmaceuticals (6 scored calls on this stock), 13.9% average gain per call, +3 pts vs its sector.
Neutral
Our verdict — RBC Capital ranks #62 of 65 in our leaderboard: 9.5% hit rate on Regeneron Pharmaceuticals (21 scored calls on this stock), 9% average gain per call, -2 pts vs its sector.
Bullish
Our verdict — HSBC ranks #19 of 65 in our leaderboard: 63.9% hit rate across all stocks, 16.1% average gain per call, +7 pts vs its sector.
Neutral
Our verdict — Leerink Partners ranks #64 of 65 in our leaderboard: 61% hit rate across all stocks, -0.7% average gain per call, -6 pts vs its sector.
Neutral
Our verdict — Citigroup ranks #22 of 65 in our leaderboard: 71.4% hit rate on Regeneron Pharmaceuticals (7 scored calls on this stock), 21.6% average gain per call, +6 pts vs its sector.
Bullish
Our verdict — Guggenheim ranks #49 of 65 in our leaderboard: 66.7% hit rate on Regeneron Pharmaceuticals (9 scored calls on this stock), 13.5% average gain per call, +3 pts vs its sector.
Neutral
Our verdict — RBC Capital ranks #62 of 65 in our leaderboard: 9.5% hit rate on Regeneron Pharmaceuticals (21 scored calls on this stock), 9% average gain per call, -2 pts vs its sector.
Neutral
Our verdict — Morgan Stanley ranks #48 of 65 in our leaderboard: 80% hit rate on Regeneron Pharmaceuticals (20 scored calls on this stock), 12.5% average gain per call, +3 pts vs its sector.
Bullish
Our verdict — Cantor Fitzgerald ranks #7 of 65 in our leaderboard: 58.6% hit rate across all stocks, 38.2% average gain per call, +13 pts vs its sector.
Neutral
Our verdict — Wells Fargo ranks #45 of 65 in our leaderboard: 64.3% hit rate on Regeneron Pharmaceuticals (14 scored calls on this stock), 14.7% average gain per call, +3 pts vs its sector.
Bullish
Our verdict — Truist Securities ranks #50 of 65 in our leaderboard: 55% hit rate on Regeneron Pharmaceuticals (20 scored calls on this stock), 14.8% average gain per call, +3 pts vs its sector.
Bullish
Our verdict — Guggenheim ranks #49 of 65 in our leaderboard: 66.7% hit rate on Regeneron Pharmaceuticals (9 scored calls on this stock), 13.5% average gain per call, +3 pts vs its sector.
⚠️ Price targets as published by the firms, timestamped at their publication date. The upside shown is vs the price on the day of the call, not today's price. Informational data, not investment advice.
Frequently asked questions
What are analysts saying about REGN right now?
Over the last 90 days, 17 price targets were published on Regeneron Pharmaceuticals: 9 bullish and 0 bearish (53% positive). The median target is $795. The latest call is from October 8, 2026.
Should you trust these price targets?
Not blindly — that's the point of this page: next to each call we show the firm's real track record — its rank among 65 tracked firms, its hit rate and its average gain per call. An ambitious target from a firm that is wrong 6 times out of 10 is not worth the same as one from a consistent firm.
Which firm covering REGN is the most reliable?
Among the firms that published on Regeneron Pharmaceuticals in the last 90 days, our highest-ranked is Cantor Fitzgerald (rank 7 of 65, 58.6% hit rate, 38.2% average gain per call).
Where does this data come from?
From analyst price targets, timestamped at publication then replayed against the actual price. Firm rankings come from our analyst leaderboard. Updated daily.
💬 A question about Regeneron Pharmaceuticals? The JPI assistant answers using our backtest data.
Keep exploring Regeneron Pharmaceuticals